This author has not written his bio yet.
But we are proud to say that Dana Mooney contributed 55 entries already.
During the December 2023 San Antonio Breast Cancer Symposium, Dr. Melinda Telli presented a summary of research that has led to better treatments for triple-negative breast cancer (TNBC). These treatments […]
Despite national guidelines recommending genetic testing, less than 10 percent of eligible patients had genetic testing within two years after their cancer diagnosis. Among those who had testing, 10-30 percent […]
This XRAY review is a summary of FDA breast cancer updates from July to December 2023. This includes a new drug approval and two consumer updates.
The FDA approved Truqap plus Faslodex for the treatment of metastatic hormone receptor-positive (HR-positive), HER2-negative breast cancer that returned or worsened after treatment with hormone therapy. The approval is for […]
The U.S. Food and Drug Administration (FDA) has released a new fast track designation for IDE161, an inhibitor of poly (ADP-ribose) glycohydrolase (PARG) to treat adult patients with advanced or […]
Metastatic Breast Cancer Alliance
28 West 44th Street
Suite 609
New York, NY 10036